Abstract 2169
Background
Cancer patients and their caregivers are expected to take joint responsibility with regard to reporting symptoms and seeking medical assistance e.g. by calling oncology emergency telephones or other helplines during their cancer trajectory. This responsibility may pose additional burdens on patients and caregivers when they are at home with symptoms that can be potential life threatening. Furthermore, in this vulnerable situation, the ability to handle the responsibility is compromised, which may influence safeguarding fundamentals of care needs. Therefore, the objective of this study is to explore the meaning of responsibility as it appeared in patients or caregivers calls to an oncology emergency telephone.
Methods
Qualitative description and qualitative content analysis guided a secondary analysis and interpretation of data from interviews with 12 participants calling an oncology emergency telephone.
Results
The analysis revealed two main themes. 1). To act responsibly as patient or caregivers was elaborated by: ‘Being watchful and alert’, ‘Reporting the symptoms’, and ‘Cross checking’. 2). To deal with the burden of responsibility was elaborated by the sub-themes: ‘Feeling safe in dealing with the burden of responsibility’, and ‘Being relieved from the burden of responsibility’.
Conclusions
Conclusion: The study provided essential knowledge on how patients and caregivers handle responsibility in their everyday living with a cancer disease, treated on an outpatient basis. The meaning of responsibility appeared in the informants’ capacity to act where they displayed responsibility to observe, assess and report symptoms and control prescribed treatment as well as to share or hand over the responsibility to the healthcare providers. Easing the burden of responsibility requires a person-centered approach that integrates physical, psychosocial and relational needs and bridge a potential imbalance between healthcare providers’ expectations and the patients’ or caregivers knowledge and capacity to act. For this to succeed, establishing a caring relationship between HCPs, patients and caregivers is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birgith Pedersen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract